{"id":"durvalumab-gemcitabine-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis)"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Durvalumab is a PD-L1 inhibitor that restores anti-tumor T-cell immunity by blocking the interaction between PD-L1 on tumor cells and PD-1 on immune cells. Gemcitabine and cisplatin are chemotherapy agents that directly damage tumor DNA and induce apoptosis. The combination leverages chemotherapy's immunogenic cell death to enhance durvalumab's checkpoint inhibition effect.","oneSentence":"This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:15.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable or metastatic biliary tract cancer"},{"name":"Potentially resectable or unresectable pancreatic cancer (in development)"}]},"trialDetails":[{"nctId":"NCT06050252","phase":"PHASE2","title":"Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-10","conditions":"Resectable Intrahepatic Cholangiocarcinoma","enrollment":27},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT06282575","phase":"PHASE3","title":"Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-07-19","conditions":"Biliary Tract Cancer","enrollment":286},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":"Biliary Tract Cancer","enrollment":620},{"nctId":"NCT07107750","phase":"PHASE1","title":"Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma","enrollment":48},{"nctId":"NCT03875235","phase":"PHASE3","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-16","conditions":"Biliary Tract Neoplasms","enrollment":810},{"nctId":"NCT07221253","phase":"PHASE3","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-04","conditions":"Biliary Tract Cancer","enrollment":1100},{"nctId":"NCT03732677","phase":"PHASE3","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-16","conditions":"Muscle Invasive Bladder Cancer","enrollment":1063},{"nctId":"NCT07332351","phase":"PHASE2","title":"Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-06-01","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":33},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT03003962","phase":"PHASE3","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-01-02","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":669},{"nctId":"NCT06858735","phase":"PHASE2","title":"HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-10","conditions":"Advanced Intrahepatic Cholangiocarcinoma","enrollment":60},{"nctId":"NCT06859684","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-03-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab","enrollment":25},{"nctId":"NCT02453282","phase":"PHASE3","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-07-21","conditions":"Non-Small-Cell Lung Carcinoma NSCLC","enrollment":1118},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate","enrollment":150},{"nctId":"NCT02542293","phase":"PHASE3","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-03","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":953},{"nctId":"NCT03819465","phase":"PHASE1","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-27","conditions":"Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":175},{"nctId":"NCT07326137","phase":"","title":"A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-26","conditions":"Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain","enrollment":103},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT03682068","phase":"PHASE3","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":1246},{"nctId":"NCT07229625","phase":"PHASE3","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-21","conditions":"Advanced Biliary Tract Cancer","enrollment":604},{"nctId":"NCT02516241","phase":"PHASE3","title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-02","conditions":"Urothelial Cancer","enrollment":1126},{"nctId":"NCT07364305","phase":"PHASE2","title":"HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-01-01","conditions":"ICC, Advanced Cancer","enrollment":50},{"nctId":"NCT06591520","phase":"PHASE3","title":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2024-10-20","conditions":"Biliary Tract Cancer","enrollment":682},{"nctId":"NCT06548412","phase":"PHASE1, PHASE2","title":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-22","conditions":"Metastatic Biliary Tract Cancer","enrollment":50},{"nctId":"NCT07351591","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":88},{"nctId":"NCT06855225","phase":"PHASE2","title":"A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Mehmet Akce","startDate":"2026-03","conditions":"Combined Hepatocellular and Cholangiocarcinoma","enrollment":29},{"nctId":"NCT07235007","phase":"NA","title":"Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Aichi Medical University","startDate":"2025-11-20","conditions":"Extrahepatic Cholangiocarcinoma","enrollment":120},{"nctId":"NCT06501625","phase":"PHASE1, PHASE2","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-12-16","conditions":"Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation","enrollment":52},{"nctId":"NCT06252753","phase":"","title":"Observational Study Protocol: LIVER-R","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-16","conditions":"Hepatobiliary Cancers","enrollment":4490},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT06546969","phase":"PHASE1","title":"Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2024-10-29","conditions":"Biliary Tract Cancer, Cholangiocarcinoma","enrollment":15},{"nctId":"NCT06440993","phase":"PHASE2","title":"Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2024-08-23","conditions":"Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA","enrollment":42},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT05422690","phase":"PHASE2","title":"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2024-06-12","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":16},{"nctId":"NCT04521686","phase":"PHASE1","title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-10-01","conditions":"Cholangiocarcinoma, Chondrosarcoma, Glioma","enrollment":200},{"nctId":"NCT05451043","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-07-05","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer","enrollment":62},{"nctId":"NCT03800134","phase":"PHASE3","title":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-06","conditions":"Non-Small Cell Lung Cancer","enrollment":825},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT03406650","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2018-05-15","conditions":"Urothelial Cancer","enrollment":61},{"nctId":"NCT06214572","phase":"PHASE2, PHASE3","title":"Radiation Therapy in Unresectable Gall Bladder Cancer","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-03-07","conditions":"Gall Bladder Cancer","enrollment":249},{"nctId":"NCT05655949","phase":"PHASE2","title":"Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-02-13","conditions":"Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable","enrollment":30},{"nctId":"NCT04308174","phase":"PHASE2","title":"Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asan Medical Center","startDate":"2020-05-20","conditions":"Biliary Tract Neoplasms, Gallbladder Cancer, Cholangiocarcinoma","enrollment":45},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06274879","phase":"PHASE2","title":"Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-06-01","conditions":"Bile Duct Cancer","enrollment":36},{"nctId":"NCT06708858","phase":"PHASE2","title":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Dai, Guanghai","startDate":"2024-08-15","conditions":"Advanced Biliary Tract Cancer","enrollment":35},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06017297","phase":"PHASE2","title":"Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma","status":"WITHDRAWN","sponsor":"Georgetown University","startDate":"2024-12","conditions":"Borderline Resectable Carcinoma, Biliary Tract Cancer","enrollment":""},{"nctId":"NCT06341764","phase":"PHASE2","title":"Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-09-01","conditions":"Cholangiocarcinoma","enrollment":38},{"nctId":"NCT04989218","phase":"PHASE1, PHASE2","title":"Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-30","conditions":"Cholangiocarcinoma","enrollment":1},{"nctId":"NCT06611345","phase":"NA","title":"A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers","status":"RECRUITING","sponsor":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","startDate":"2024-10-21","conditions":"Biliary Tract Cancers (BTC)","enrollment":60},{"nctId":"NCT06591650","phase":"PHASE2","title":"Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-09-10","conditions":"Gallbladder Cancer Unresectable","enrollment":33},{"nctId":"NCT06567600","phase":"PHASE2","title":"Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-09-01","conditions":"Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy","enrollment":43},{"nctId":"NCT03421353","phase":"PHASE1","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-02-07","conditions":"Advanced Solid Tumours","enrollment":76},{"nctId":"NCT06502080","phase":"PHASE2","title":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07","conditions":"Biliary Tract Cancer","enrollment":128},{"nctId":"NCT06375915","phase":"PHASE2","title":"Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy","status":"RECRUITING","sponsor":"Francesco De Cobelli","startDate":"2024-05-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":33},{"nctId":"NCT03046862","phase":"PHASE2","title":"Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2017-02-25","conditions":"Biliary Tract Neoplasms","enrollment":31},{"nctId":"NCT06255262","phase":"PHASE1, PHASE2","title":"Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2024-02-15","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT03912818","phase":"PHASE2","title":"Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-04-10","conditions":"Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT03473574","phase":"PHASE2","title":"Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-05-02","conditions":"Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable","enrollment":128},{"nctId":"NCT04617756","phase":"PHASE2","title":"Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-09-29","conditions":"Urothelial Carcinoma, Cancer","enrollment":50},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT05672537","phase":"PHASE2","title":"Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-20","conditions":"Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis","enrollment":70},{"nctId":"NCT05640791","phase":"PHASE2","title":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-12-01","conditions":"Resectable Biliary Tract Cancer","enrollment":40},{"nctId":"NCT05383001","phase":"PHASE2","title":"Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","status":"WITHDRAWN","sponsor":"AIO-Studien-gGmbH","startDate":"2022-05-20","conditions":"NSCLC Stage IV","enrollment":""},{"nctId":"NCT02658214","phase":"PHASE1","title":"Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-04-28","conditions":"Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms","enrollment":32},{"nctId":"NCT04073160","phase":"PHASE1","title":"TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer","status":"WITHDRAWN","sponsor":"Daniel George, MD","startDate":"2020-06","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT04447612","phase":"PHASE2","title":"Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Durvalumab, Gemcitabine, Cisplatin","genericName":"Durvalumab, Gemcitabine, Cisplatin","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death. Used for Unresectable or metastatic biliary tract cancer, Potentially resectable or unresectable pancreatic cancer (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}